Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | OPRL1 | P41146 | 12/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.40 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3732741 | 0.92 | OPRL1 (0.52) | OPRL1OPRM1OPRK1 | |
| SCHEMBL13078159 | 0.87 | L3MBTL1 (0.38) | LMNAMAPTALDH1A1MEN1KMT2A | |
| SCHEMBL3729068 | 0.82 | OPRL1 (0.54) | OPRL1ALDH1A1MEN1KMT2AEGLN1 | |
| SCHEMBL3742691 | 0.81 | EGLN1 (0.47) | OPRL1ALDH1A1KMT2AEGLN1OPRM1 | |
| SCHEMBL3733515 | 0.81 | OPRL1 (0.54) | LMNAOPRL1MAPTALDH1A1MEN1 | |
| SCHEMBL3730232 | 0.80 | HSD11B1 (0.50) | LMNAOPRL1MAPTEGLN1 | |
| SCHEMBL3738860 | 0.79 | OPRL1 (0.52) | LMNAOPRL1ALDH1A1MEN1KMT2A | |
| SCHEMBL3735041 | 0.76 | OPRL1 (0.55) | LMNAOPRL1ALDH1A1EGLN1 | |
| SCHEMBL3739308 | 0.76 | OPRL1 (0.50) | OPRL1ALDH1A1EGLN1SMN1; SMN2OPRM1 | |
| SCHEMBL3742780 | 0.74 | OPRL1 (0.53) | OPRL1MEN1KMT2AEGLN1OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100280049-A1 | ANTAGONISTS OF PGD2 RECEPTORS | AMIRA PHARMACEUTICALS, INC. (US) | 2010-11-04 | — | — | US | disclosed |
| US-20100280049-A1 | ANTAGONISTS OF PGD2 RECEPTORS | AMIRA PHARMACEUTICALS, INC. (US) | 2010-11-04 | — | — | US | disclosed |
| US-20100280049-A1 | ANTAGONISTS OF PGD2 RECEPTORS | AMIRA PHARMACEUTICALS, INC. (US) | 2010-11-04 | — | — | US | disclosed |
| WO-2009061676-A2 | ANTAGONISTS OF PGD2 RECEPTORS | AMIRA PHARMACEUTICALS, INC. (US) | 2009-05-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100280049-A1 | ANTAGONISTS OF PGD2 RECEPTORS | PTGDR2, PTGDR, LTB4R2 | LMNA 4153/4885OPRL1 233/4885MAPT 4781/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.